Altogether, these data establish that the functional outcome of P1C4 therapy—tumor rejection versus immune-mediated toxicity—relies on the specific co-expression of CXCR3, CCR5, and CXCR6 on responding T cells. This evidence concerns the gene CXCR3 and neoplasm.